Your session is about to expire
← Back to Search
IO-202 + Pembrolizumab for Solid Tumors
Study Summary
This trial is testing a new drug, IO-202, to see if it is safe and effective in treating patients with advanced solid tumors. The trial will also help determine the recommended dose of IO-202 for future trials.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have tried at least one treatment for my condition without success.You are allergic to any of the ingredients in the IO-202 formulation or pembrolizumab.I have no active cancer except for certain skin cancers, low-risk prostate cancer, or any cancer treated over 6 months ago.I need more than 10 mg of prednisone or its equivalent daily.I haven't had major heart or stroke issues in the last 6 months.I have an advanced cancer and cannot take standard treatments.I am fully active or restricted in physically strenuous activity but can do light work.I have symptoms from a brain tumor.You have another serious medical or mental health condition that may make it risky for you to participate in the study, or that could affect the study results. The doctor will decide if it's best for you to join the study.I have had severe side effects from previous immunotherapy.I do not have any active infections, including HBV, HCV, HIV, SARS-COV-2, or AIDS.I haven't had cancer treatment or fully recovered from its side effects recently.I have had lung inflammation or scarring not caused by an infection.I do not have serious heart rhythm problems.I have not been treated with drugs targeting LILRB or ILT.My heart's pumping ability is significantly reduced.
- Group 1: IO-202 Monotherapy (dose escalation)
- Group 2: IO-202 + pembrolizumab combination therapy (dose expansion)
- Group 3: IO-202 dose escalation + pembrolizumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have the reported risks been concerning IO-202?
"There is minimal clinical evidence backing the safety of IO-202, thus it earned a score of 1."
Is this exploration still available for participation?
"Clinicaltrials.gov indicates that this trial is not currently accepting applicants, despite initially being posted on April 1st 2022 and edited as recently as March 25th 2022. Although the study is inactive at present, there are a plethora of other trials actively recruiting participants right now."
Are there several sites in the US that are currently administering this experiment?
"This clinical investigation is currently enrolling patients across 4 distinct medical sites. These include Houston, LA and Nashville as well as a few other facilities. To minimize travel pressure during the course of this trial, it's best to select the closest center for your convenience."
What is the primary aim of this medical experiment?
"As reported by the trial sponsor Immune-Onc Therapeutics, this study's primary outcome is assessing dose-limiting toxicities in regards to IO-202 and IO-202 + pembrolizumab over a two year period. Secondary outcomes include characterizing minimum concentration of IO-202 through blood sampling; determining preliminary rates of response after treatment with IO 202; and examining immunogenicity associated with both medications."
Share this study with friends
Copy Link
Messenger